Status:

UNKNOWN

Efficacy and Safety of Nipent, Cytoxan and Rituxan in the Treatment of Chronic Lymphocytic Leukemia.

Lead Sponsor:

East Valley Hematology and Oncology Medical Group

Collaborating Sponsors:

Mena, Raul, M.D.

Pharmatech Oncology

Conditions:

Chronic Lymphocytic Leukemia

Eligibility:

All Genders

18+ years

Phase:

PHASE4

Brief Summary

This research study measures the safety and efficacy of the combination of three drugs that are approved, Nipent, Rituxan and Cytoxan in the treatment of Chronic Lymphocytic Leukemia (CLL). These drug...

Detailed Description

Chronic Lymphocytic Leukemia (CLL) is the most common form of adult leukemia in the U.S. Recent experience with Nipent in conjunction with Rituxan has shown that this combination is well tolerated and...

Eligibility Criteria

Inclusion

  • Stage II, III or IV Chronic Lymphocytic Leukemia
  • Disease requires chemotherapeutic treatment
  • CT or MRI scan confirming measurable tumor size
  • Documentation of CD markers
  • Up to one prior treatment regimen
  • Expected survival greater than 6 months
  • ECOG performance status of 0-2
  • Adequate renal, bone marrow and liver functions
  • Negative pregnancy test (females of childbearing potential)
  • Must agree to use acceptable birth control, if fertile
  • Must complete Informed Consent
  • No heart disease and must have adequate cardiac function
  • Must test negative for viral Hepatitis B and C

Exclusion

  • More than one prior treatment for Chronic Lymphocytic Leukemia
  • Known sensitivity to Nipent, Rituxan or Cytoxan or any component of these drugs
  • Known HIV or AIDS illness
  • Thyroid disease requiring medication
  • History of any malignancy that could affect the diagnosis or assessment of the study treatment
  • Pregnancy or breast feeding
  • Evidence of Hepatitis B or C infection
  • Inability to comply with the requirements of the study

Key Trial Info

Start Date :

January 1 2003

Trial Type :

INTERVENTIONAL

End Date :

April 1 2009

Estimated Enrollment :

180 Patients enrolled

Trial Details

Trial ID

NCT00131313

Start Date

January 1 2003

End Date

April 1 2009

Last Update

August 18 2005

Active Locations (52)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 13 (52 locations)

1

Northwest Alabama Cancer Center, PC

Muscle Shoals, Alabama, United States, 35661

2

East Valley Hematology and Oncology Medical Group

Burbank, California, United States, 91505

3

Bay Area Cancer Research Group

Concord, California, United States, 94520

4

Lalita Pandit, MD, Inc.

Fountain Valley, California, United States, 92708